| 1 |
32970826 | Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration. | 2021 May |
1 |
| 2 |
24262967 | Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele. | 2014 Jan 20 |
3 |
| 3 |
25343291 | Enantioselective N-demethylation and hydroxylation of sibutramine in human liver microsomes and recombinant cytochrome p-450 isoforms. | 2014 |
1 |
| 4 |
22830954 | Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. | 2013 Feb |
4 |
| 5 |
23381968 | Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects. | 2013 May |
3 |
| 6 |
23777987 | Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes. | 2013 Sep 5 |
7 |
| 7 |
20350955 | Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. | 2011 Jan |
3 |
| 8 |
21209232 | Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. | 2011 Dec |
6 |
| 9 |
19693007 | Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. | 2009 Nov |
2 |
| 10 |
19702527 | Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. | 2009 Sep |
1 |
| 11 |
18474675 | Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. | 2008 Aug |
7 |